← Return to When is forteo prescribed and when is evenity prescribed?

Discussion
Comment receiving replies
@gently

oh, Teb. I think you have later information than I have. https://pmc.ncbi.nlm.nih.gov/articles/PMC4947115/#:~:text=Summary%20In%20patients%20with%20osteoporosis,outcomes%20than%20shorter%20time%20periods.
Of course your own experience trumps anything written in these studies.
I would be interested in your bone markers throughout, if you have them handy and are willing.
I had a slow rise in bone markers in the first year and no real change in bmd, but a little change in fracture risk. The second year gave me real changes in P1NP plus changing my lowest reading from -3.3 to -2.6. If the bone markers are any measure this next dxa will show even more improvement.
The burst of hormone is a daily trick. The rise of P1NP instigates the rise of CTX which eventually exceeds the advantage of P1NP.
Were you able to get bone markers ordered every few months. The endocrinologist I see gave me a standing order for every three months. And I depend upon Jason Health for the rest. It is good to hear your results.

Jump to this post


Replies to "oh, Teb. I think you have later information than I have. https://pmc.ncbi.nlm.nih.gov/articles/PMC4947115/#:~:text=Summary%20In%20patients%20with%20osteoporosis,outcomes%20than%20shorter%20time%20periods. Of course your own..."

I took Forteo about 9-10 years ago. If I recall correctly, my doctor ordered one set of bone marker tests in the first few months to determine it was working and then a dexa at one year. Unfortunately, I wasn't as informed back then on the importance of bone markers so I did not request it on a regular basis. At the time, I was under the care of two endocrinologists who specialize in osteoporosis management and they just followed the drug manufacturer's recommendation with little thought as to personalization and optimization. Along those lines, one thing that makes me somewhat skeptical of the study cited (other than my personal experience of losing density the second year of treatment) is that it was sponsored/paid for by Ely Lily with all authors involved either employees, investors or consultants which gives rise to a slant towards recommendation of full compliance of a 2 year protocol. It does state that "a clinical trial in which patients are randomized to different durations of teriparatide treatment has not been performed"